MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • The neurosteroid dehydroepiandrosterone sulfate (DHEAS) reverses the dopaminergic deficiencies in mild hepatic encephalopathy: A possible therapeutic issue for the management of parkinsonism in cirrhotic patients

    O. El Hiba, H. Gamrani (Marrakesh, Morocco)

  • The NIC-PD-study –Baseline data of a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson’s disease in Germany and the USA

    W.H. Oertel, C. Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, H. Mueller, M.M. Unger, K.M. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

  • The non-motor side of the honey-moon period of Parkinson’s disease

    R. Erro, M. Picillo, C. Vitale, M. Amboni, M. Moccia, M.T. Pellecchia, P. Barone (London, United Kingdom)

  • The non-motors symptoms in Parkinson’s disease patients with freezing of gait

    H.C. Huang, M.K. Lu, C.H. Tsai (Taichung, Taiwan)

  • The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination

    J. Ellmen, J. Tuunainen, A. Holopainen, T. Sarapohja, M. Scheinin (Turku, Finland)

  • The nucleocytoplasmic transport of ataxin-3 as pathogenic mechanism in spinocerebellar ataxia type 3

    T. Schmidt, A. Sowa, I.M. Martins, M. Abedi, Z. Wang, J. Schmidt, H. Tricoire, O. Riess (Tübingen, Germany)

  • The Parkinson progression marker initiative (PPMI) – Developing a comprehensive longitudinal biomarker dataset

    Parkinson Progression Marker Initiative (New Haven, CT, USA)

  • The patient’s perspective: The effect of dopamine on Parkinson symptoms

    H. Zach, M.F. Dirkx, J.W. Pasman, B.R. Bloem, R.C. Helmich (Vienna, Austria)

  • The patterns of olfactory function in Parksinson’s disease patients with mild cognitive impairment

    J.W. Park, H.K. Yoon, M.H. Park, D.Y. Kwon (Ansan, Korea)

  • The phenotypic and genetic features of myoclonus-dystonia in six Saudi Arabian kindreds

    S.A. Bohlega, A. Aldakheel, T. Alkhairallah, A. Alkhani, M. Almuhaizea, F. Alotaibi (Riyadh, Saudi Arabia)

  • « Previous Page
  • 1
  • …
  • 187
  • 188
  • 189
  • 190
  • 191
  • …
  • 207
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley